CERK and neoplasm: The role of CerK in BCs is ascertained by several studies that documented both an overexpression of this enzyme in more than 2000 patients with different BCs subtypes and clinical pathological characteristics and its correlation with tumor aggressivity and poor clinical outcome following adjuvant or neoadjuvant therapy (Table 1) [56,57].